Watch for Compass's next communication with the FDA and any decision on whether to conduct a new survival trial. The stock will likely react negatively to the FDA's requirement for additional data, which pushes out the BLA timeline and increases development costs and risk.
Price Chart
Executive Summary
Compass Therapeutics disclosed that the FDA recommended conducting an additional trial demonstrating a survival benefit before submitting a BLA for tovecimig in biliary tract cancer. The company disagrees with the FDA's position and intends to further engage the agency, but the regulatory path is now uncertain and likely delayed. This is a material negative regulatory setback for the company's lead pipeline asset.
Key Facts
- FDA recommended Compass conduct a trial demonstrating a survival benefit before BLA submission for tovecimig in BTC
- Compass does not believe a new trial is warranted and intends to further engage with the FDA
- COMPANION-002 showed ORR 18.0% vs 5.3% (p=0.0228), median PFS 4.7 vs 2.6 months (HR 0.44, p<0.0001)
- Overall survival analyses did not meet statistical significance due to high crossover and prolonged survival in crossover patients
- Tovecimig has Fast Track and Orphan Drug Designation from the FDA
Financial Impact
Regulatory delay for lead pipeline asset tovecimig; no financial data provided in filing
Risk Factors
- BLA submission delayed or denied without a new survival trial
- Additional trial would require significant capital and extend timeline by years
- Potential for complete clinical hold or negative FDA advisory committee vote
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-006162 |
| Exhibit: exh_991.htm | 0001171843-26-006162 |
| Document: 0001171843-26-006162-index-headers.html | 0001171843-26-006162 |
| Document: 0001171843-26-006162-index.html | 0001171843-26-006162 |
| Document: 0001171843-26-006162.txt | 0001171843-26-006162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $0.7472 | awaiting T+20 | — | $0.7470 (−0.03%) |
Sep 22, 2026 5w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7470 (+39.76%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7470 (−68.88%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7470 (−63.56%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7470 (−67.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7470 (−63.20%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7470 (−63.91%) |
May 5, 2026 25w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7470 (−61.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers